About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Understanding Why and How a Class of Leukemia Drugs is Successful

by Dr. Trupti Shirole on December 5, 2016 at 6:00 PM
Font : A-A+

 Understanding Why and How a Class of Leukemia Drugs is Successful

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia, with over 4,000 cases in the United Kingdom every year. At the moment CLL is incurable, but in recent years, new drugs called B-cell receptor (BCR) inhibitors, have revolutionized treatment.

However, it is not entirely clear how they work and why they are so effective. In addition, some patients can become resistant to these types of drugs.

Advertisement


Researchers at the University of Southampton have shed new light on why and how this new class of drug is effective at fighting off leukemia.

The study, led by Professor Mark Cragg at the University of Southampton and funded by The Kay Kendall Leukemia Fund and Bloodwise, has characterized the molecular mechanisms responsible for how one of these drugs (idelalisib) work.
Advertisement

Published in the journal Leukemia, the study treated blood cells from CLL patients in the laboratory with idelalisib and found it disrupts important survival signals from within the tumor and prevents communication from surrounding cells that help the tumor survive; causing the tumor cells to die.

The response to idelalisib was linked to an increased production of a protein called Bim, which is responsible for the tumor cell death. Their results also showed idelalisib-like drugs can be successfully combined with antibody treatments to more effectively eradicate the cancer and give longer lasting protection and that this combination effect is also dependent on Bim.

Professor Cragg said, "These results are very interesting and positive. We now know how the drug is able to attack and slow the growth of the tumors, but not get rid of it completely. We also know that Bim is required for the death and for the combination effects with antibody treatments. With this knowledge we can design better, more effective combination treatments. In the future, we could even be looking at combinations that will give us a cure for some blood cancers where we don't currently have that possibility."

Dr. Alasdair Rankin, Director of Research at Bloodwise, said, "Idelalisib and other BCR inhibitors have transformed the outlook for patients with CLL, but we are still not entirely clear how they work and why they are so effective. We now have a rising number of treatments available to people with CLL. A deeper understanding of how these drugs work is needed to guide treatment decisions and identify combinations that deliver the best benefits for patients."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Liver Transplantation
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Multiple Myeloma Amyotrophic Lateral Sclerosis (ALS) Drugs Banned in India Bone Marrow Transplantation Hairy Cell Leukemia 

Most Popular on Medindia

Calculate Ideal Weight for Infants Loram (2 mg) (Lorazepam) Sanatogen Blood Pressure Calculator Blood - Sugar Chart Turmeric Powder - Health Benefits, Uses & Side Effects Noscaphene (Noscapine) How to Reduce School Bag Weight - Simple Tips Pregnancy Confirmation Calculator Sinopril (2mg) (Lacidipine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use